Abstract
Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have